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Introduction {#sec0005}
============

Healthcare-associated infections (HAIs) like bacteremia caused by multidrug-resistant *Pseudomonas aeruginosa* strains result in an increased morbidity and mortality, prolonging the hospitalization, and higher costs compared to those infections caused by susceptible strains.[@bib0245], [@bib0250], [@bib0255] Infections caused by these resistant microorganisms are often associated with age, cancer, heart disease, diabetes, intensive use of antibiotics, and invasive procedures such as hemodialysis, mechanical ventilation catheter, tracheostomy, and others.[@bib0260]

The increasing incidence of multidrug-resistant *P. aeruginosa* as a cause of nosocomial infection is a global problem, a consequence of the ability of this microorganism to develop resistance to almost all other antimicrobial agents during antimicrobial chemotherapy, either by selection of mutations in chromosomal genes or by horizontal gene transfer.[@bib0265], [@bib0270] In Brazil, this problem is even more significant, since there is a very high density of antibiotic use, especially β-lactams, carbapenems, and fluoroquinolones.[@bib0275], [@bib0280] The resistance in *P. aeruginosa* to carbapenems is up to 60% in some Brazilian hospitals[@bib0285], [@bib0290] and mainly occurs by production of metallo-β-lactamases (MBL).

Ten subclasses of the MBL enzymes are known: IMP (Imipenemase), VIM (Verona Imipenemase), SPM-1 (São Paulo MBL), GIM (German Imipenemase), SIM-1 (Seul Imipenemase),[@bib0295] AIM-1 (Australian Imipenemase),[@bib0300] KHM (Kyorin University Hospital),[@bib0305] NDM-1 (New Delhi MBL),[@bib0310] DIM-1 (Dutch Imipenemase),[@bib0315] and TMB (Tripoli MBL).[@bib0320] In Brazil, the most prevalent subclasses are IMP-1 and SPM-1.[@bib0295]

Several other virulence genes as well as biofilm formation may contribute to the pathogenicity of severe infections, particularly including those associated with invasive procedures.[@bib0325] Among the major virulence factors described in the literature, we highlight those related to the adherence of microorganisms to host cells through the flagella, fimbriae, and alginate[@bib0330] and those that facilitate the disruption of epithelial integrity and interfere with the immune system, such as elastase, phospholipase C and protease alkaline, further exotoxin A, pyocyanin, and pyoverdine.[@bib0335] The biofilm production is particularly associated with the difficulty of antibiotics to penetrate the cells, since them secrete a polymeric matrix composed of polysaccharides, proteins, and DNA.[@bib0340], [@bib0345]

The aim of this study was to identify the risk factors associated with bacteremia caused by carbapenem-resistant *P. aeruginosa* as well as the production of MBL. Additionally, we investigated the frequency of virulence genes and their ability to form biofilm.

Materials and methods {#sec0010}
=====================

Patients and hospital {#sec0015}
---------------------

The *P. aeruginosa* strains were recovered from patients admitted to the Uberlandia University Hospital (Brazil), Federal University of Uberlândia (HC-UFU), and obtained from the Microbiology Laboratory of the HC-UFU, during the period from May 2009 to December 2012, considering only the first episode of infection.

Study design {#sec0020}
------------

We conducted a case (patients with bacteremia due to *P. aeruginosa* resistant to carbapenems) *versus* control (patients with bacteremia caused by *P. aeruginosa* susceptible to carbapenems) study to identify risk factors among patients infected with *P. aeruginosa* resistant to carbapenems. Additionally, we evaluated secondary outcomes, including periods of hospitalization, admission to the intensive care unit (ICU), and use of invasive procedures. Demographic, clinical, and epidemiological characteristics of each patient included in the study were recovered from the clinical records.

Definitions {#sec0025}
-----------

Healthcare-associated infections (HAIs) are defined as any infection acquired after a patient\'s admission to the hospital. HAIs may manifest during hospitalization or after discharge, since they are related to hospitalization or procedures performed during the hospitalization.[@bib0350] Bacteremia, according to the Centers for Disease Control and Prevention,[@bib0355] can be defined as the presence of viable bacteria in the blood documented by a positive blood culture result. Bacteremia was classified as primary when it was unrelated to another focus of infection or when it was related to an intravenous catheter, and secondary when it was clinically related to infection in another anatomic site.[@bib0285] Multidrug-resistance is defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories.[@bib0360] The antimicrobial therapy was considered inappropriate when an isolated microorganism presented *in vitro* resistance to antimicrobials used for treating the patient and/or a lack of treatment for 24 h after diagnosis of microbial infections.[@bib0365]

Clinical microbiological and molecular testing {#sec0030}
----------------------------------------------

Cultures were collected according to the protocol used by the Microbiology Laboratory of the HC-UFU and were processed using the automated system BACT/Alert^®^ (BioMérieux, Durham, USA). The identification and antimicrobial susceptibility tests were performed by automation using the VITEK II system and the strains that showed intermediate susceptibility were considered resistant. Quality-control protocols were used according to the standards of the Clinical and Laboratory Standard Institute.[@bib0370], [@bib0375], [@bib0380] The carbapenem-resistant *P. aeruginosa* isolates were phenotypically screened for MBL production using double-disc synergy tests, as previously described.[@bib0385], [@bib0390] In addition, to assess the presence of MBL genes in *P. aeruginosa* strains, a multiplex PCR was performed, as described previously.[@bib0395] The cycling conditions were: 94 °C for 5 min, followed by 30 denaturation cycles at 94 °C for 30 s, annealing at 53 °C for 45 s and extension at 72 °C for 30 s, followed by final extension at 72 °C at 10 min, all in a MasterCycler personal (Eppendorf). Detection of virulence genes codifying alkaline protease (*aprA*), elastase A (*lasA*), elastase (*lasB*),[@bib0400] haemolytic phospholipase C (*plcH*), non-haemolytic phospholipase C (*plcN*), exotoxin A (*toxA*) and alginate (*algD*)[@bib0405] were determined by uniplex PCR, using the following protocol: 94 °C for 3 min, 30 cycles at 94 °C for 30 s, 55 °C for 1 min and 72 for 1 min and 30 s and 72 °C for 5 min.

Initial adhesion assay[@bib0410] {#sec0035}
--------------------------------

In order to evaluate the initial adhesion, 200 μL of a cell suspension containing 1 × 10^7^ cells/mL prepared in TSB was added to 96-well polystyrene plates. Initial adhesion was allowed to occur for 2 h at 37 °C with rotation at 120 rpm. Bacteria adhered in 96-well polystyrene plates were washed twice with a 0.9% NaCl solution and harvested by scraping the wells for 90 s. The cell suspension obtained was plated on TSA for colony-forming unit (CFU) enumeration. All experiments were done in triplicate in three independent experiments. The strain ATCC15692 (PAO1) was used as a positive control and TSB without bacteria was used as a negative control.

Biofilm formation assay[@bib0415] {#sec0040}
---------------------------------

200 μL of a cell suspension containing 1 × 10^7^ cells/mL prepared in TSB was added to 96-well polystyrene plates. Biofilm formation was allowed to occur for 24 h at 37 °C with rotation at 120 rpm. Bacteria grown in 96-well polystyrene plates were washed twice with a 0.9% NaCl solution and left to dry in an inverted position. The total biomass was measured by methanol (Merck) fixation, crystal violet (Merck) staining, and acid acetic (Merck) elution as previously described. The eluted dye was removed from each well and placed in a new 96-well microtiter plate, and its absorbance was read on an ELISA plate reader (BioTek Instruments Inc., Vermont, USA) at 570 nm. The experiments were done with eight replicates for each strain in three independent experiments. TSB without bacteria was used as a negative control. The optical density cut-off value (ODc) was established as three standard deviations (SD) above the mean of the optical density (OD) of the negative control: ODc = average OD of negative control + 3x SD of negative control. For easier interpretation of the results, strains were divided into the following categories according to optical density: (ODi): ODi ≤ ODc or ODc \< ODi \< 2x ODc = non-biofilm producer/weak biofilm producer; 2x ODc \< ODi \< 4x ODc = moderate biofilm producer; 4x ODc \< ODi = strong biofilm producer.

Biofilm cell concentration[@bib0420] {#sec0045}
------------------------------------

The biofilm cell concentration was determined by CFU enumeration. After biofilm formation, the biofilms were washed twice with a 0.9% NaCl solution and harvested after scraping the wells for 90 s. The cell suspension obtained was plated onto TSA plates. All experiments were done in triplicate, on three independent occasions.

Statistical analysis {#sec0050}
--------------------

Statistical analysis was performed using GraphPad Prism v.5 (GraphPad Software, San Diego, CA). Quantitative assays were compared using the Kruskal--Wallis, applying Dunn\'s multiple comparison test. All tests were performed with a confidence level of 95% and statistical significance was defined as *p* \< 0.05.

Ethical approval {#sec0055}
----------------

The research Ethics Committee of the Federal University Uberlandia evaluated and approved our study design.

Results {#sec0060}
=======

From May 1, 2009, to December 31, 2012, a hospital surveillance of the incidence of *P. aeruginosa* bacteremia was performed in the microbiology laboratory of the University Hospital. In this period, 157 non-repetitive patients with *P. aeruginosa* bacteremia were included in the study. The detailed information on factors associated with the development of bacteremia and the clinical and demographic characteristics, as well the distribution of patients by wards are shown in [Table 1](#tbl0005){ref-type="table"}, [Table 2](#tbl0010){ref-type="table"}. The primary bacteremia occurred in 75.8% and those with unknown focus accounted in 62.4% of the cases. Secondary bacteremia accounted for 24.2% of patients, where the respiratory tract was the main focus of infection (17.2%). Furthermore, 43.9% of patients had bacteremia with carbapenem-resistant *P. aeruginosa*, and most of these patients were admitted to the ICU. Most patients were male (66.8%), with an average hospital stay of 63.2 ± 80.17 days and an average age of 52.01 ± 20.24 years.Table 1Distribution of patients infected with *Pseudomonas aeruginosa* in different units of the Clinical Hospital of the Federal University of Uberlândia from May/2009 to December/2012.Table 1ClinicsTotalCarbapenem-resistant *Pseudomonas aeruginosaN* = 157 (%)*N* = 69 (%)Surgery35 (22.3)16 (23.2)Medical clinic24 (15.3)10 (14.5)Oncology14 (8.9)2 (2.9)Emergency room9 (5.7)5 (7.3)ICU[a](#tblfn0005){ref-type="table-fn"}50 (31.9)31 (44.9)Neonatal ICU2 (1.3)0Pediatric ICU2 (1.3)1 (1.5)Transplant2 (1.3)0Others[b](#tblfn0010){ref-type="table-fn"}3 (1.9)0[^1][^2]Table 2Risk factors associated with carbapenem resistance in patients with bacteremia caused by *Pseudomonas aeruginosa*.Table 2Risk factorsTotalCarbapenem resistantMultisensitive[a](#tblfn0015){ref-type="table-fn"}UnivariateMultivariate*N* = 157 (%)*N* = 69 (%)*N* = 65 (%)OR[b](#tblfn0020){ref-type="table-fn"} (CI[c](#tblfn0025){ref-type="table-fn"} 95%)*p*[d](#tblfn0030){ref-type="table-fn"}OR (CI 95%)*pAge-mean (years)*52.01 ± 24.4959.01 ± 20.2443.18 ± 27.56--0.0009[\*](#tblfn0040){ref-type="table-fn"}----*Male/female*105/52 (66.88/33.12)45 (65.22)/24 (34.78)43 (66.15)/22 (33.85)0.9593 (0.4698--1.959)0.9092----*Time of hospitalization, mean (days)*63.2 ± 80.1760.01 ± 48.9768.86 ± 110.4--0.3477----*Intensive care unit*74 (47.13)38 (55.07)22 (33.85)2.396 (1.190--4.822)0.0135----*Surgery*69 (43.95)37 (53.62)20 (30.77)2.602 (1.281--5.282)0.0075[\*](#tblfn0040){ref-type="table-fn"}----  *Invasive procedures (72* *h)*139 (88.53)64 (92.75)54 (83.08)2.607 (0.8527--7.973)0.0843---- Mechanical ventilation89 (56.69)48 (69.56)28 (43.08)3.020 (1.485--6.144)0.002[\*](#tblfn0040){ref-type="table-fn"}3.0674 (1.22--7.73)0.0175 Tracheostomy70 (44.58)43 (62.32)17 (26.15)4.670 (2.234--9.759)\<0.0001[\*](#tblfn0040){ref-type="table-fn"}---- Urinary catheter101 (64.33)52 (75.36)34 (52.31)2.789 (1.340--5.804)0.0054[\*](#tblfn0040){ref-type="table-fn"}---- Venous central catheter125 (79.62)59 (85.51)48 (73.85)2.090 (0.8761--4.984)0.0926---- Surgical drain24 (15.29)14 (20.29)7 (10.77)2.109 (0.7918--5.618)0.1297---- Probes enteral/gastric nutrition109 (69.43)54 (78.26)40 (61.54)2.250 (1.053--4.810)0.0345[\*](#tblfn0040){ref-type="table-fn"}3.8347 (1.43--10.26)0.0074 Hemodialysis39 (24.84)27 (39.13)8 (12.31)4.580 (1.892--11.09)0.0004[\*](#tblfn0040){ref-type="table-fn"} Parenteral nutrition25 (1.92)14 (20.29)8 (12.31)1.814 (0.7052--4.664)0.2125----  *Comorbidity conditions*122 (77.70)53 (76.81)49 (75.38)1.082 (0.4886--2.394)0.8465---- Heart failure35 (22.29)21 (30.43)12 (18.46)1.932 (0.8597--4.343)0.1079---- Cancer32 (20.38)8 (11.59)17 (26.15)0.3703 (0.1473--0.9308)0.0306---- Diabetes mellitus21 (13.37)9 (13.04)7 (10.75)1.243 (0.4341--3.558)0.6849---- Chronic renal failure40 (25.48)21 (30.43)16 (24.61)1.340 (0.6249--2.873)0.4514---- Human immunodeficiency virus10 (6.37)5 (7.25)3 (4.61)1.615 (0.3699--7.048)0.7191----  *ASIS*[e](#tblfn0035){ref-type="table-fn"}*score* *≥* *4*81 (51.59)35 (50.72)33 (50.77)0.9982 (0.5068--1.966)0.9959----  *Primary bacteremia*119 (75.79)45 (65.22)57 (87.69)0.2632 (0.1080--0.6413)0.0023[\*](#tblfn0040){ref-type="table-fn"}---- Central line catheter related21 (13.37)11 (15.94)7 (10.75)1.571 (0.5693--4.338)0.3802---- Unknown98 (62.42)34 (49.27)50 (76.9)0.2914 (0.1383--0.6143)0.00090.2363 (0.08--0.73)0.0127  *Secondary bacteremia*38 (24.20)24 (34.78)8 (12.31)3.800 (1.559--9.260)0.0023[\*](#tblfn0040){ref-type="table-fn"}---- Respiratory tract27 (17.19)17 (24.64)5 (7.69)3.923 (1.353--11.37)0.0081[\*](#tblfn0040){ref-type="table-fn"}---- Urinary tract6 (3.82)4 (5.79)1 (1.54)3.938 (0.4282--36.22)0.3666----  *Inappropriate therapy*49 (31.21)32 (46.37)8 (12.31)6.162 (2.560--14.83)\<0.0001[\*](#tblfn0040){ref-type="table-fn"}8.5534 (3.28--22.32)\<0.0001*Previous use of antibiotics*123 (78.34)59 (85.51)43 (66.15)3.019 (1.297--7.025)0.0086[\*](#tblfn0040){ref-type="table-fn"}----*Mortality*92 (58.59)48 (69.56)32 (49.23)2.357 (1.163--4.779)0.0165[\*](#tblfn0040){ref-type="table-fn"}2.3660 (1.15--4.85)0.0186[^3][^4][^5][^6][^7][^8]

The previous use of antibiotics (78.3%), invasive procedures (88.5%), comorbidities (77.7%), and prior surgery (43.9%) were common. It was found that 31.2% of patients received inadequate treatment, and the death rate was 58.6%. Several intrinsic and extrinsic factors for the development of bacteremia by strains of *P. aeruginosa* resistant to carbapenems were detected by univariate analysis. However, only mechanical ventilation, enteral/nasogastric tubes, primary bacteremia with unknown focus, and inappropriate therapy were risk factors independently associated with the development of carbapenem-resistant *P. aeruginosa* bacteremia.

MBL production was analyzed for 56 carbapenem-resistant *P. aeruginosa* isolates. Nine (25.0%) isolates were phenotypically positive and a total of 16.1% (n= 9/56) were consistent with the amplicons MBL genes, being 10.71% *bla*~SPM-1~ and 5.3% *bla*~VIM~ genes In general, the strains showed a multidrug resistance profile. For other virulence genes evaluated (*aprA*, *plcH*, *plcN*, *lasA*, *lasB*, *toxA*, and *algD*), all strains showed a high frequency (88%).

Among the 88 carbapenem-susceptible *P. aeruginosa* strains, 21 (23.9%) were resistant to other β-lactams. For 69 strains resistant to carbapenems, the resistance profile was high: β-lactam 50/69 (72.5%), fluoroquinolones 48/69 (69.6%), and aminoglycosides 50/69 (72.5%) ([Table 3](#tbl0015){ref-type="table"}).Table 3Antimicrobial resistance profiles in samples of *Pseudomonas aeruginosa* isolated from blood.Table 3AntimicrobialCarbapenems*p* (OR)Resistant group\
*N* = 69 (%)Susceptible group\
*N* = 88 (%)Ceftazidime51 (73.9)10 (11.4)\<0.0001 (9.446--51.71)Cefepime45 (65.2)17 (19.3)\<0.0001 (3.792--16.17)Piperacillin/tazobactam37 (53.6)12 (13.6)\<0.0001 (3.386--15.84)Fluorquinolones (ciprofloxacin and levofloxacin)48 (69.6)17 (19.3)\<0.0001 (4.568--19.95)Aminoglicosides (amikacin and gentamicin)50 (72.5)12 (13.6)\<0.0001 (7.442--37.32)

In addition to MBL research, five strains were selected (two containing SPM-1, one containing VIM, and two phenotypically positive for MBL) to the evaluation of the biofilm formation using quantitative assays of total biomass by staining with crystal violet. Considering the presence of MBL genes, all strains were identified as strongly biofilm producers with an average of 0.90 ± 0.61 of biomass. Differences in initial adhesion of individual strains were not observed. However, there was a lower OD for the strain containing the *bla*~VIM~ gene ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1(A) Number of cells adhered to a polystyrene surface after 2 h, expressed as log CFU/mL for 5 samples of *Pseudomonas aeruginosa* isolated from blood. (B) Number of viable cells in the biofilm (log CFU/mL). (C) Biomass of biofilm expressed as optical density of crystal violet (OD~570nm~).

Discussion {#sec0065}
==========

Hospital bacteremia caused by multiresistant microorganisms, whether Gram-positive or Gram-negative, has often been described as a significant health problem that increases hospital costs and makes it difficult to establish an appropriate antimicrobial therapy, which results in a worse prognosis.[@bib0425] The high proportion of hospital bacteremia caused by *P. aeruginosa* resistant to carbapenems indicates the importance of this organism as a significant cause of this infection in our hospital. The high proportion of hospital bacteremia caused by *P. aeruginosa* resistant to carbapenems indicates the importance of this organism as a significant cause of this infection in our hospital. The results of different studies have suggested that intrinsic risk factors such as mechanical ventilation, use of a nasogastric tube, and prior use of antibiotics increase the risk of bacteremia development caused by *P. aeruginosa* resistant to carbapenems, as well as the risk of morbidity and mortality.[@bib0430]

In this study, more than 50% of the risk factors were associated with infection by this microorganism according to univariate analysis. However, only mechanical ventilation, enteral/gastric feeding tubes, primary bacteremia of unknown origin, and inappropriate treatment were considered independent risk factors by multivariate analysis.

A central venous catheter is one of the most significant risk factors for acquired bacteremia in the hospital, as it was associated with more than 90% of these infections.[@bib0435] Although it was not a significant risk factor in this study, 85.5% of patients with bacteremia with carbapenem-resistant *P. aeruginosa* had this invasive procedure.

Often, bacteremia caused by *P. aeruginosa* resistant to antibiotics has a higher mortality rate due, in particular, to the administration of inappropriate antibiotic therapy.[@bib0440] In this study, we investigated a cohort of 157 patients with bacteremia caused by *P. aeruginosa* strains, with 69 of them infected by carbapenem-resistant *P. aeruginosa* isolates. Total mortality was higher in the carbapenem-resistant group; however, the presence of resistant strains was significantly associated with inappropriate antimicrobial therapy, proving that this group usually has a poorer prognosis. Similar to our findings, previous studies showed that *P. aeruginosa* isolated from patients who received inappropriate therapy had a worse prognosis, with rates of 46.1%[@bib0445] and 53.8%.[@bib0450]

Besides to be associated with severe infections, resistance to carbapenems in *P. aeruginosa* often results in the production of MBL.[@bib0455] Our results showed that the carbapenem-resistant *P. aeruginosa* were prevalent throughout the hospital with genes that encoding these enzymes in 16.1% of the strains, being 10.7% of genotype *bla*~SPM-1~ and 5.4% of genotype *bla*~VIM~. Since the frequency of multidrug-resistant strains was high, these results suggest that other resistance mechanisms coexist in these strains, such as efflux pumps and impermeability of the membrane.[@bib0460]

The prevalence of MBL as a resistance mechanism has increased, particularly in Latin America.[@bib0465] In Brazil, the prevalence of MBL-producing *P. aeruginosa* varies between different regions and between hospitals, with rates ranging from 7.5% to 44%.[@bib0295]

SPM-1 enzyme is considered the most common in Brazil, followed by IMP-1,[@bib0295], [@bib0470] however, there has also been an increase in the frequency of *P. aeruginosa* isolates containing VIM enzyme.[@bib0465], [@bib0475] In our study, the SPM-1 enzyme was detected in 16.7% of phenotypically producing samples of MBL, followed by VIM enzyme, which was detected in 8.3% of cases. These results indicate a significant spread of MBL-encoding genes in our region.

Considering the presence of MBL and biofilm production, 100% of the strains were classified as strong producers. Another study in Brazil found that 40% of *P. aeruginosa* classified as strong biofilm-producing were also MBL producers.[@bib0415] We believe that these results are important once these characteristics (biofilm production and MBL) overlap and infections caused by these bacteria are difficult to treat. This is justified, in part, because the growth of bacteria in the biofilm is about 64 times more resistant to antimicrobial.[@bib0480]

*P. aeruginosa* has a large number of extracellular virulence factors that also contribute to the pathogenicity and severity of these infections, such as that encoded by *aprA*, *plcH*, *plcN*, *lasA*, *lasB*, *toxA*, and *algD* genes.[@bib0400], [@bib0405] Our data showed that the presence of a multiresistant profile, in the most of the strains (88%) were positive for the *aprA*, *plcH*, *plcN*, *lasA*, *lasB*, *toxA*, and *algD* virulence genes, except in one strain that did not show the *toxA* and *plcH* genes, which can further contribute to a worse prognosis associated with severe infections.

Our results confirm previous findings regarding risk factors for the development of *P. aeruginosa* carbapenem-resistant bacteremia, as well as the dissemination of MBL-producing strains of SPM-1 type. However, this study contributes for further evidence of the spread of MBL-producing strains, particularly the VIM type, in highly virulent strains and strongly biofilm producers.
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[^1]: Intensive care unit.

[^2]: Burneds, thoracic pain unit.

[^3]: Multisensitive strains were considered as those who presented susceptibility to all antimicrobials tested.

[^4]: Odds ratio.

[^5]: Confidence interval.

[^6]: *p* value.

[^7]: Average severity of illness score.

[^8]: Statistically significant (P≤0.05).
